Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Senseonics Holdings Inc

Senseonics Holdings Inc (SENS)

( 0.78% )
Updated: 14:27:25

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.4504 Day's Range 0.47
0.365 52 Week Range 0.9694
Market Cap
Previous Close
Last Trade
Last Trade Time
Financial Volume
$ 341,214
Average Volume (3m)
Shares Outstanding
Dividend Yield
PE Ratio
Earnings Per Share (EPS)
Net Profit

About Senseonics Holdings Inc

Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of the glucose monitoring system, which helps people to manage their diabetes. Its products and services include Continuous glucose monitoring system, Sensor, Smart transmitter, a... Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of the glucose monitoring system, which helps people to manage their diabetes. Its products and services include Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States. Show more

Computer Programming Service
Industrial Measurement Instr
Wilmington, Delaware, USA
Senseonics Holdings Inc is listed in the Computer Programming Service sector of the American Stock Exchange with ticker SENS. The last closing price for Senseonics was $0.46. Over the last year, Senseonics shares have traded in a share price range of $ 0.365 to $ 0.9694.

Senseonics currently has 530,886,421 shares outstanding. The market capitalization of Senseonics is $244.63 million. Senseonics has a price to earnings ratio (PE ratio) of -4.04.

SENS Latest News

Senseonics Holdings, Inc. Provides Business Update and Full Year 2024 Financial Outlook

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems...

Senseonics Holdings, Inc. to Host Business Update and Analyst Event During the American Diabetes Association’s 84th Scientific Sessions

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems...

Senseonics Holdings, Inc. to Participate in the Sidoti Small Cap Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP


View all
  • Most Active
  • % Gainers
  • % Losers
$ 2.34
POAIPredictive Oncology Inc
$ 1.88
PBMPsyence Biomedical Ltd
$ 0.6389
SLRXSalarius Pharmaceuticals Inc
$ 3.1501
CMAXCareMax Inc
$ 5.625
$ 1.5323
EZFLEzFill Holdings Inc
$ 3.75
KDLYKindly MD Inc
$ 2.11
CTNTCheetah Net Supply Chain Service Inc
$ 0.3235
SLGLSol Gel Technologies Ltd
$ 0.4554
NVDANVIDIA Corporation
$ 114.25
SQQQProShares UltraPro Short QQQ
$ 9.0763
SLNASelina Hospitality PLC
$ 0.03985
POAIPredictive Oncology Inc
$ 1.89
TSLATesla Inc
$ 224.46

SENS Discussion

View Posts
antman antman 3 months ago
So I guess they are taking this one down to zero now.too?
Monksdream Monksdream 9 months ago
Wall Street Millennial
$5.95akadawson-m $5.95akadawson-m 9 months ago
saw you on the Ballard and FCEL board with the identical message. What's UP?
Monksdream Monksdream 10 months ago
SENS new 52 week low
Monksdream Monksdream 11 months ago
SENS new 52 week low
$5.95akadawson-m $5.95akadawson-m 11 months ago
That’s definitely one slanted view.
Monksdream Monksdream 11 months ago
Apparently the better mouse trap didn’t make it
$5.95akadawson-m $5.95akadawson-m 11 months ago
What happened? I thought the company had a alternative delivery system?
Monksdream Monksdream 11 months ago
SENS new 52 week low
antman antman 1 year ago
Price keeps recovering slowly but surely
LRD LRD 1 year ago
Sens is ready to skyrocket. No reason why Sens is not $3+.
subslover subslover 1 year ago
SenesTech Announces Development and Distribution Agreement for ContraPest® in South Africa
PHOENIX, June 1, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), ( the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, announced entry into a Development and Distribution Agreement with Pathogens and Environmental Solutions (PES) of South Africa for the commercialization of ContraPest® into South Africa. Under the agreement, PES will be responsible for seeking regulatory registration, and all marketing and sales of ContraPest into South Africa.

"South Africa is a leading sub-Saharan economy with an active pest control industry focused on the agricultural and public health applications of pest control. We were introduced to South Africa and PES by the South African National Council of SPCAs (NSPCA), who are continuing to advise us, and who clearly articulated their support for fertility control and ContraPest in particular. They have committed to recommend ContraPest to private and state entities and to assist with regulatory issues," said Joel Fruendt, SenesTech's President and CEO.

"NSPCA brought in PES as being an excellent partner for us in this project, as they have extensive experience in securing registration and launching commercialization of pest control products. Specifically, PES is a leading manufacturer and distributor of rodent pest control products, with an explicit goal to constantly grow their range of products by adding innovative products for integrated pest management (IPM)," continued Mr. Fruendt. "While we are starting in South Africa, I have no doubt that we will be able to expand our work with PES across its sub-Saharan territories."

"At PES we aim to bring innovative products to the African Sub-Saharan region. Contrapest fits this aim perfectly, and partnering with Senestech was a logical fit for us at PES, as we are always looking for industry leading products," said Reon Hillebrand, Director at PES. "Once regulatory approval is achieved, we look forward to offering our customers this unique rodent control alternative, complementing our current rodent control offering in South Africa and our other African partners."

About SenesTech
We are the experts in rat fertility control. Our passion is to create a healthy environment by better controlling rat pest populations. We keep an inescapable truth in mind. Two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year. We invented ContraPest, the only U.S. EPA registered contraceptive for male and female rats. ContraPest fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rat management. We strive for clean cities, efficient businesses, and happy households – with a product that was designed to be effective and sustainable without killing rats. At SenesTech, we are committed to improving the
$5.95akadawson-m $5.95akadawson-m 2 years ago
well, SENS, has been on a mad dash down for the past the ten months.
turning stone turning stone 2 years ago
turning stone

Re: None

Wednesday, December 14, 2022 3:23:30 PM

of 215813

I still have a small number of shares but I will be moving them also. At almost 78 time is not on my side to wait. I was not happy after listening to the latest research crap. a f m d and s e n s are my hope now and I am heavy there. If you are young enough I hope CYDY gets bought up by some other company and you get to make some dollars. I have enjoyed crushing the market over the years and continue to live off of it.
$5.95akadawson-m $5.95akadawson-m 2 years ago
If you’re still in CYDY, I’m all ears.
turning stone turning stone 2 years ago
Okay people TURNING STONE Bought A nice chunk of shares in SENS and I like to talk about the company and what I see ahead for it in my opinion. so I expect some people to come back at me with nice an not so nice comments.
leemalone2k3 leemalone2k3 2 years ago
I am. Just waiting for the next pop to sell some short term calls against my LEAPS.
antman antman 2 years ago
Are you still holding? It just drops and drops
Wild N Free Wild N Free 2 years ago
Love this company :) Picked up some last week
nbm16yankees nbm16yankees 2 years ago
Thanks for getting back to me.
I noticed that the 85 cent premium was as high as $1.04 on Monday 8/22 when share price dropped to 1.69. Now that it is back up to $1.85 premium is at 95 cents.
My personal feeling is that the share price is on the right upward path and we will see
$3 or more by Jan as sales increase.
I wish they would advertise on TV like the others are doing. I live in a retirement community and I try to tell people about our CGM all the time. No one has heard of it.

Anyway, thanks for your help. GLTA
leemalone2k3 leemalone2k3 2 years ago
You are correct in your strategy. If you sell them at .80 and it closes above the strike you keep the premium. If it closes below it you are put the stock at a cost of 1.70. If it closes ATM you may or may not be put the stock. You could close your contract for a few cents though. Whenever I am put the stock, I then sell covered calls against it until you are called out. Then go back to selling puts.

I typically only sell puts out three months because it takes so long for the premium to decay if you go out longer in time.
nbm16yankees nbm16yankees 2 years ago
Haven't been on the board in awhile.
Just curious what you think of selling Jan 20, 2023 2.5 Puts at 80/85 cents?
Or do you think a different strike price would be a better play?

And just confirming what I think I know.....
If it closes above the strike price on that date, I keep the premium
If it closes below the strike price on that date, I own the stock unless I buy puts back
at whatever price.

What if it closes AT the strike price?

Thanks in advance....
leemalone2k3 leemalone2k3 2 years ago
My favorite long term hold.
Holding 2024 2.00 calls at .30
Holding stock at 1.83, selling covered calls against them on pops.

Senseonics Holdings' Elevance Diabetes System Secures Coverage Under Elevance Health; Shares Rise

8/3/22, 11:18 AM
11:18 AM EDT, 08/03/2022 (MT Newswires) -- Senseonics Holdings (SENS) said Wednesday that US insurance company Elevance Health has agreed to provide coverage for the Eversense continuous glucose monitoring system.

The device is designed to continually measure glucose levels in people aged 18 and over with diabetes for up to six months. It is meant to replace fingerstick blood glucose measurements for diabetes treatment decisions.

With the Elevance Health coverage, over 45 million people across 14 states would be able to add the Eversense system to their health plans, Senseonics said.

Shares of the medical technology company were up more than 16% in recent trading activity.
LRD LRD 2 years ago
Hold on because there’s more to come Sens is going to go very high this year. Starting 2023 off very great
leemalone2k3 leemalone2k3 2 years ago
Sorry I wasn’t able to respond quickly.
That’s decent premium on those May 3.00 puts. They already gained .20 in profit over a week. I think it is still good premium to sell at 1.22. I probably would not buy the May calls unless I was expecting news or an event regarding the company. With the stock trading so low the only calls I’ll buy are LEAPS.
nbm16yankees nbm16yankees 2 years ago
A lot of activity in the May 20th $3 calls and $3 puts. Over 10500 of each.
Calls last price 7 cents
Puts last price $1.42

Is that a certain type of play?
What do you think of just selling those puts?
As always, thanks in advance
leemalone2k3 leemalone2k3 2 years ago
I understand your reasoning for going out that long in time. I use this strategy to buy stocks short term but in a case like SENS where it’s a penny stock it’s difficult to collect premium out of the money with short term strikes.

I don’t know the answer to the buyout question. In all the years I’ve been trading that situation has never occurred to me. Probably would be best to ask your broker.
nbm16yankees nbm16yankees 2 years ago
thanks for responding.
What you say makes a lot of sense.
I'm just feeling my way with PUTS, as I have not written too many.
I usually sell covered calls and have enjoyed much success.
But my reasoning for going out so long, is I believe SENS will do well in 6-9 months. So if they put the stock to me at $1.50 then I am using my money for other ventures. I like the company very much,
but their guidance IMO, tells me we need to be patient.

So, my next question to you regards what happens to the put if there is a buyout at say 5 or 6 dollars +/- ? Does the price drop accordingly and gives me the chance to buy it back at much cheaper price, or do they put it to me at $1.50?

Much thanks for your input and education.
leemalone2k3 leemalone2k3 2 years ago
My strategy to selling naked puts is short to mid term time frames, typically no longer than 45 days.
nbm16yankees nbm16yankees 2 years ago
thanks for the update.

I have been mulling over writing some Jan 20, 2023 $1.50 puts.
Friday they closed at 54 cents.
Any thoughts?
leemalone2k3 leemalone2k3 2 years ago
Update on Positions. New option position.

I rolled the Jan 2023 2.00 calls into Jan 2024 2.00 calls. It cost me .30/contract to execute this trade.
Option positions
Bought Jan 2024 calls 1.02
Wrote March 4.00 calls .42
When the March calls expire my adjusted cost on the 2024 calls will be .60 (1.02-.42)

Still holding my covered stock
Bought stock 2.25
Wrote March 4.00 calls .42
When the March calls expire the adjusted cost of the stock will be1.83. (2.25-.42)

leemalone2k3 leemalone2k3 2 years ago
Brilliant trading. Trading spreads has some advantages but one drawback to buying options outright.
Higher probability of a winning trade.

The stock doesn’t have to move as much, or in some cases not at all to make a profit. Also the stock doesn’t have move as far to make 100% or higher gains. .

You can be wrong about direction and still not lose equity as quickly and salvage losing trade with less losses

A drawback is you are limited on gains
3antar 3antar 2 years ago
I'm ready to add but I don't know how far would she go any ideas
nbm16yankees nbm16yankees 2 years ago
Thanks again.
I dipped into 3 of those puts at .32 each.
I may go back for 2 more tomorrow at .36 or so.
I believe in the company and think it will rebound. I believe I will make money on these either way, as I wont mind buying them if I have to.
The Jan calls I have I sold 10 at average 75 cents each. So I have a pretty good profit.
Thinking of buying them back and then waiting for spike in price and sell something greater in value but lower in strike price.

Your strategy sounds pretty good and I hope to use it again in some other positions.
leemalone2k3 leemalone2k3 2 years ago
I like using this strategy to buy stocks after huge sell offs. The volatility is cranked up so the options get super overvalued, increasing the probability of them expiring worthless . It may or may not be a win/win especially if the stock is below 1.70 on expiration.

As far as your Jan 2023 10.00 calls go I would guess your position ( not sure what you paid) is down significantly but don’t have any good advice on them other than to hold or add if you think the stock will make it back to recent heights in a short to medium timeframe. Or dump them if you don’t believe the above scenario.

nbm16yankees nbm16yankees 2 years ago
Thanks for the explanation. Sounds like a win, win.

Heretofore I have only sold covered calls. But writing (selling) a put at this price level sounds pretty good to me. I envision the share price going back up near term, and long term I think we will be richly rewarded.
Always appreciate reading your ideas.

I still have my Jan 23 $10 calls. Whats our advice there.
MCA MCA 2 years ago
New here, unfortunately took a starter position just before the FDA news. Why are the '22 projections so low? Any chance they will improve now that they can go to market?

leemalone2k3 leemalone2k3 2 years ago
Wrote 20 March 2.00 puts today at .30.
If SENS closes above 2.00 on March 18 I keep that premium. If SENS closes below 2.00, I’ll own the stock at 1.70 on March 21st.
Ralph11 Ralph11 2 years ago
Probably, be bought out. But no where close to 10.00 pps
Teaks Teaks 2 years ago
I’m holding for sure. This was my long term hold after reading about them awhile back.
trendzone trendzone 2 years ago
Shorts getting burned after hours on Ho,Ok, could the same kind of news happen here and squeeze and burn the recent shorters, anything is possible in the market these days.
nbm16yankees nbm16yankees 2 years ago

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for March 1, 2022, at 4:30 p.m. Eastern Time

February 15, 2022

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Tuesday, March 1, 2022.

Management will hold a conference call to review the Company’s fourth quarter and full year 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 2775821, approximately ten to five minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

View source version on

Senseonics Investor Contact

Lynn Lewis or Philip Taylor

Investor Relations


Source: Senseonics Holdings, Inc.

<< Back to 2022 News Releases
teifhals teifhals 2 years ago
So…. Whens that buyout?
Gpheart2016 Gpheart2016 2 years ago
SENS has provided better care for diabetics and this company will become profitable (IMO). Unfortunately, we have not made money as investors on the good news. The best advice is to hold or accumulate more shares now and wait a year or two for the big payday.
nbm16yankees nbm16yankees 2 years ago
Ascensia issues positive PR

February 14 2022 - 07:00AM
PR Newswire (US)

PARSIPPANY, N.J., Feb. 14, 2022 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces that its partner Senseonics Holdings, Inc. (NYSE American: SENS) has received approval from the U.S. Food and Drug Administration (FDA) for the next-generation Eversense® E3 Continuous Glucose Monitoring (CGM) System. Ascensia plans to make the Eversense E3 sensor, which can be used for up to 6 months, available to patients in the U.S. during the second quarter of 2022.
Ascensia Diabetes Care logo

Robert Schumm, President at Ascensia Diabetes Care, said, "As the world's first and only long-term CGM System, Eversense is truly innovative and the prospect of using a single sensor for 6 months is a huge step forward for people with diabetes. Ensuring that as many people as possible have access to Eversense E3 is key for us and we'll be introducing a program to help users experience Eversense affordably as we work closely with payers on coverage. We look forward to rolling out this next-generation system through our dedicated CGM commercial team in the U.S. in the coming months, as we strive to improve the lives of people with diabetes everywhere."

Developed by Senseonics and brought to people with diabetes by Ascensia, the newly approved Eversense E3 CGM System, which includes a sacrificial boronic acid (SBA) design modification to enhance sensor survival, offers patients:

The longest lasting CGM available, with 6-month sensor wear duration and essentially two sensor insertion and removal procedures per year
Exceptional accuracy, with a mean absolute relative difference (MARD) of 8.5% demonstrated in the PROMISE Study1 for the duration of sensor wear
A fully implantable fluorescence-based sensor, with a removable smart transmitter* that provides discreet on-body vibratory alerts and transmits data to a mobile app
Fewer calibrations, with primarily one calibration required per day after day 21 of use

"This next generation system delivers on the patient's desire for a CGM sensor that is both long-lasting and highly accurate," said Elaine Anderson, Head of Eversense CGM Business Unit at Ascensia Diabetes Care. "Its unique features and benefits offer people with diabetes unparalleled flexibility, convenience and accuracy. Our partner Senseonics has designed Eversense E3 with the user in mind and we are excited to bring the system to people in the U.S. in the second quarter."

To be among the first to know when Eversense E3 is commercially available, patients who are interested in getting started with Eversense now can sign up at Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at Alternatively, contact 844-SENSE4U (844-736-7348) to learn more about the first and only long-term implantable CGM system.

* There is no glucose data generated when the transmitter is removed.
1 Garg S. et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182

View original content:

SOURCE Ascensia Diabetes Care

Copyright 2022 PR Newswire
LRD LRD 2 years ago
Taking bids. To buy SENS or to sell Sens. If it’s good news I buy it goes down. If it goes down i buy it goes lower So for the right bid I will either buy or sale on your request
Teaks Teaks 2 years ago
Makes no sense.
da_stock_analyst da_stock_analyst 2 years ago
#SENS?? FDA approved and 33% down!! Where is it going? Time to get back in or avoid? #senseonics
leemalone2k3 leemalone2k3 2 years ago
Update on positions
Stock fell today on news.
This week I wrote March 4.00 calls at .42 (they peaked at .60) against my stock and against my LEAPS.
Now holding
Covered Stock
Stock price 2.25
Written calls .42
I’ll be buying theses calls back at .05 or lower which will adjust the price of the
stock down .37-.42 to 1.88-1.83 price.

Holding purchased 23jan 2.00 calls .72
Wrote (sold) March 4.00 calls at .42. I plan to buy these back at .05 or lower reducing the cost of the LEAPS down to .35-.30 cost
jonny_red jonny_red 2 years ago
That 5.50 range is my plan as well.

Your Recent History

Delayed Upgrade Clock